在具有恶化功能的异常性膜性病中使用普雷迪尼索隆和ambucil 治疗
P W Mathieson1, A N Turner, C G Maidment
1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Lancet (London, England)
|October 15, 1988
概括
这项研究表明,在患有异常性膜性腎病症的患者中,交替服用普雷尼索隆和ambucil 治疗显著降低了蛋白尿和改善了功能,即使是在功能下降的患者中也是如此.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫抑制疗法 免疫抑制疗法
背景情况:
- 异形膜性病 (IMN) 是成年人性综合征的主要原因.
- 在IMN中,可以发生渐进性功能衰竭,需要有效的治疗策略.
研究的目的:
- 评估在IMN和功能恶化的患者中交替使用普得尼索隆和ambucil的月度循环的疗效.
- 评估这种疗法对蛋白尿和功能参数的影响.
主要方法:
- 一组由8名IMN和功能下降的患者组成的队列接受了6个月的治疗过程.
- 治疗涉及交替每月周期的普雷迪尼索隆和ambucil.
- 在整个研究过程中,蛋白尿和肌素清除得到了监测.
主要成果:
- 所有患者都经历了蛋白尿的显著减少 (平均15.3g/24h至2.1g/24h).
- 肌素清除在6名患者显著改善,在2名患者稳定 (平均为51.6毫升/分钟至81.4毫升/分钟).
- ambucil的严重不良反应需要降低剂量.
结论:
- 交替使用普得尼索隆和ambucil可以改变IMN的自然过程,即使存在功能障碍.
- 这种治疗方法可能有利于高风险IMN患者,功能恶化.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
